晚期肾细胞癌患者癌症易感基因胚系突变患病率研究
该队列研究纳入254例晚期肾细胞癌患者,通过胚系测序发现16.1%存在胚系突变,其中CHEK2突变频率最高且与肾癌风险相关(OR 3.0)。
要点
- 晚期肾癌患者中胚系突变总体患病率为16.1%,CHEK2为最常见突变基因。
- 非透明细胞肾癌患者RCC相关基因突变率显著高于透明细胞癌(11.7% vs 1.7%)。
- 现行临床指南未识别出35.7%的RCC相关基因突变患者,支持更广泛的测序策略。
核心结论
- 在晚期肾细胞癌患者中,胚系突变患病率较高(16.1%),非透明细胞肾癌患者中超过20%存在胚系突变,其中一半具有指导全身治疗的潜力。
- 当前基因检测转诊标准未能识别相当一部分携带突变的患者,支持采用更广泛的测序方法。
研究设计与样本
- 本研究为队列研究,于2015年10月1日至2017年7月31日开展,共纳入254例晚期(AJCC III或IV期)肾细胞癌患者,均同意在机构协议下进行肿瘤-胚系DNA配对测序并披露结果。
- 患者中位年龄56岁(范围13-79岁),179例(70.5%)为男性,211例(83.1%)为非西班牙裔白人。
主要发现
- 41例(16.1%)患者检出胚系突变;14例(5.5%)携带综合征性RCC相关基因突变(FH 7例,BAP1 3例,VHL、MET、SDHA、SDHB各1例)。
- 最常见突变为CHEK2(9例)和FH(7例)。
- 携带RCC相关基因突变的患者中,5例(35.7%)不符合现行基因检测临床指南。
关键数值与推荐
- 胚系突变总体患病率为16.1%(41/254)。
- RCC相关基因突变患者中35.7%(5/14)不符合现行基因检测指南。
临床怎么用
- 对晚期肾细胞癌患者,尤其是非透明细胞类型,应考虑胚系基因检测以指导治疗和筛查。
- 现行转诊标准可能遗漏部分携带胚系突变的患者,提示需要更广泛的测序策略。
局限性
- 本研究为单机构队列研究,样本量有限(254例),结果外推需谨慎。
- 原文未报告随访时间、突变功能验证及治疗结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Identification of patients with hereditary renal cell carcinoma (RCC) is important for cancer screening and, in patients with advanced disease, for guiding treatment. The prevalence of cancer-related germline mutations in patients with advanced RCC and the phenotypes associated with some rare mutations are unknown. OBJECTIVES: To examine the prevalence of germline mutations in both known RCC predisposition genes and other cancer-associated genes and to identify clinical and pathologic factors associated with germline mutations. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study conducted from October 1, 2015, to July 31, 2017, 254 of 267 patients with advanced (American Joint Committee on Cancer stage III or IV) RCC who were seen in medical oncology or urology clinics agreed to germline sequencing and disclosure of results under an institutional protocol of matched tumor-germline DNA sequencing. MAIN OUTCOMES AND MEASURES: Mutation prevalence and spectrum in patients with advanced RCC were determined. Clinical characteristics were assessed by mutation status. RESULTS: Of the 254 patients (median age [range], 56 [13-79] years; 179 [70.5%] male; 211 [83.1%] non-Hispanic white), germline mutations were identified in 41 (16.1%); 14 (5.5%) had mutations in syndromic RCC-associated genes (7 in FH, 3 in BAP1, and 1 each in VHL, MET, SDHA, and SDHB). The most frequent mutations were CHEK2 (n = 9) and FH (n = 7). Of genes not previously associated with RCC risk, CHEK2 was overrepresented in patients compared with the general population, with an odds ratio of RCC of 3.0 (95% CI, 1.3-5.8; P = .003). Patients with non-clear cell RCC were significantly more likely to have an RCC-associated gene mutation (9 [11.7%] of 74 vs 3 [1.7%] of 177; P = .001), and 8 (10.0%) had a mutation in a gene that could guide therapy. Of patients with mutations in RCC-associated genes, 5 (35.7%) failed to meet current clinical guidelines for genetic testing. CONCLUSIONS AND RELEVANCE: Of patients with non-clear cell RCC, more than 20% had a germline mutation, of which half had the potential to direct systemic therapy. Current referral criteria for genetic testing did not identify a substantial portion of patients with mutations, supporting the role of a more inclusive sequencing approach.
引用
- Carlo MI, Mukherjee S, Mandelker D, et al. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncol. 2018. PMID: 29978187. doi:10.1001/jamaoncol.2018.1986
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。